A new marker for lipid peroxidation: Serum paraoxonase activity in non-alcoholic steatohepatitis

Turkish Journal of Gastroenterology

Volumn 16, Issue 3, 2005, Pages 119-123

  Başkol, Mevlüt ^a   Başkol, Gülden ^a   Deniz, Kemal ^a   Özbakir, Ömer ^a   Yücesoy, Mehmet ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Lipid peroxidation; Malondialdehyde; Non alcoholic steatohepatitis; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; MALONALDEHYDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS; HUMAN; LIPID PEROXIDATION; MALE; STEATORRHEA;

ADULT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OBESITY; SEVERITY OF ILLNESS INDEX; TURKEY;

EID: 33845298299     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003; 17: 977-86.
2. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
3. Day CP, James OFW. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-5.
4. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634-6.
5. Tilg H, Diehl AM. Mechanisms of disease: cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
7. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-23.
8. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
9. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34: 255-62.
10. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221-9.
11. Fong GD, Nehra V, Lindor KD, et al. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3-10.
12. Polavarapu R, Spitz DR, Sim JE, et al. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology 1998; 27: 1317-23.
13. Berson A, Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764-74.
14. La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999; 119-120: 379-88.
15. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmac 1998; 31: 329-36.
16. Sözmen EY, Sözmen B, Girgin FK, et al. Antioxidant enzymes and paraoxonase show a co-activity in preserving low-density lipoprotein from oxidation. Clin Exp Med 2001; 1: 195-9.
17. Kelso GJ, Stuart WD, Richter RJ, et al. Apolipoprotein J is associated with paraoxonase in human serum. Biochemistry 1994; 33: 832-9.
18. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. Arterioscler Thromb Vasc Biol 1997; 17: 2935-9.
19. Ferre N, Camps J, Prats E, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 261-8.
20. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
21. Atatruda JM, Linemeyer DL. Obesity. In: Felig F, Frohman LA, eds. Endocrinology & Metabolism. New York: McGraw- Hill Companies, 2001; 945-91.
22. Eckerson EW, Romson J, Wyte C, et al. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-27.
23. Jain SK. Evidence for membrane lipid peroxidation during the in vivo aging of human erythrocytes. Biochem Biophys Acta 1988; 937: 205-10.
24. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812-8.
25. Ikeda Y, Suehiro T, Inoue M, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin dependent diabetes mellitus. Metabolism 1998; 47: 598-602.
26. Tanimoto N, Kumon Y, Suehiro T, et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sciences 2003; 72: 2877-85.
27. Paragh G, Asztalos L, Seres I, et al. Serum paraoxonase activity in uremic and kidney-transplanted patients. Nephron 1999; 83: 126-31.
28. Schiavon R, De Fanti E, Giavarina D, et al. Serum paraoxonase activity is decreased in uremic patients. Clinica Chimica Acta 1996; 247: 71-80.
29. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
30. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000; 75: 733-9.
31. Kumon Y, Nakauchi Y, Suehiro T, et al. Proinflammatory cytokines but not acute phase serum amyloid A or reactive protein, down-regulates paraoxonase 1 (PON1) expression by HepG2. Amyloid 2002; 9: 160-4.
32. Ferre N, Camps J, Cabre M, et al. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001; 50: 997-1000.